BPC-157 half-life: how long does it last in the body?

What is the half-life of BPC-157?

The FDA review did not identify a human BPC-157 half-life (FDA, 11 May 2026). In a pharmacokinetic study with six animals per group, the average elimination half-life was 15.2 minutes in Sprague-Dawley rats and 5.27 minutes in beagle dogs, and these animal values do not describe humans (He et al., Frontiers in Pharmacology, 2022). A half-life is the time it takes the measured concentration in blood to fall by half. The FDA review dated 11 May 2026 states that there is no information to assess the pharmacokinetics of BPC-157 in humans.

A half-life is a clock that restarts after each tick. Applying the rat figure of 15.2 minutes from He et al. (Frontiers in Pharmacology, 2022; six rats per group) over an hour leaves about one-sixteenth of the starting amount, which is arithmetic, not a measured value, and it does not describe humans.

In the rat and dog study of six animals per group, the authors report no noticeable difference in plasma concentration between males and females, an animal finding that does not describe humans (He et al., Frontiers in Pharmacology, 2022). In rats and dogs, six animals per group, peak concentration and total exposure rose in proportion across three exposure levels, which the authors call linear pharmacokinetics, an animal finding that does not establish a human result (He et al., Frontiers in Pharmacology, 2022).

Evidence limits

What has not been measured about BPC-157 in humans?

The FDA review reports that most BPC-157 plasma values in the abstract covering 32 healthy male volunteers were below the assay's lower limit of quantification, with no further assay details, so those readings do not prove that no absorption occurred (Veljaca et al., 2003, as summarised by the FDA, July 2026). The same FDA review lists a 2025 pilot in two healthy adults for its safety checks, not for concentration measurements, and says it found no information to assess human pharmacokinetics (FDA, July 2026).

The animal work has gaps too. The study tested two routes in rats and dogs, neither of them oral, and the authors did not analyse metabolites in tissues because of a small sample size (He et al., Frontiers in Pharmacology, 2022; six animals per group). Whether BPC-157 may be supplied in Australia is a separate question, answered on the legal status page.

How long does BPC-157 last in the body?

The FDA briefing and PubMed records checked for this page on 14 October 2026 include no study that measured how long BPC-157 lasts in the human body. In rats and dogs, six per group, the intact peptide could not be detected in plasma 4 hours after study exposure, a finding in animals that does not describe humans (He et al., Frontiers in Pharmacology, 2022). In six rats given a radioactively labelled version, the label's half-life in plasma was 102 ± 32 hours, and 54% of the radioactivity was still in the animals' bodies 72 hours later, because the label travels with fragments and single amino acids and not only with intact BPC-157, an animal finding that does not describe humans (He et al., Frontiers in Pharmacology, 2022).

The label sat on proline, one of the amino acids the body uses to build protein. In rats, six per group, the authors found that once peptidases cut BPC-157 into pieces the labelled proline entered normal amino acid metabolism, an animal finding that does not describe humans (He et al., Frontiers in Pharmacology, 2022). Your own body does the same with the proline in a meal.

Anti-doping laboratories have built urine tests for BPC-157. A 2017 laboratory urine method reported a detection limit of 0.1 ng/mL and stability for at least 4 days, with no sample count in the abstract and no measured human detection window (Cox et al., Drug Testing and Analysis, 2017). A 2023 laboratory urine method detected BPC-157 and five main metabolites at limits of 0.01 to 0.11 ng/mL, with no sample count in the abstract and no measured human detection window (Tian et al., Molecules, 2023). Neither study reports how long a test stays positive after exposure, so a detection window is not established in these studies.

How quickly does BPC-157 act, according to studies?

The FDA briefing and PubMed records checked for this page on 14 October 2026 include no human study that measured how long BPC-157 takes to produce any effect. The animal pharmacokinetic study measured arrival, not effect: in six animals per group, plasma concentration peaked at 3 minutes in rats and between 6.33 and 8.67 minutes in dogs, animal values that do not describe humans (He et al., Frontiers in Pharmacology, 2022). In a 2008 rat study of surgically made colon-to-skin fistulas, the authors examined animals on days 1, 3, 5, 7, 14, 21 and 28 after surgery, with a group size not given in the abstract, and the rat result does not carry over to people (Klicek et al., Journal of Pharmacological Sciences, 2008).

The FDA review summarises that rat study: from day 3 after surgery, fistulas in treated rats were about 40% smaller than in vehicle-treated rats, a rat result, with a group size not given in the FDA summary, that the review qualifies because no relationship between exposure level and effect could be established, the authors gave no tissue-integrity data, and whether the effect would hold at a different stage of injury is unknown (FDA briefing document, July 2026).

A concentration in blood is not an effect. A peptide can reach its peak in minutes, and whether anything changes in tissue, and when, depends on the model and on what was measured. The FDA briefing and PubMed records checked on 14 October 2026 did not identify a study linking BPC-157 blood levels to an effect, and the FDA review states that the molecular targets of BPC-157 have not been identified and its mechanisms remain poorly understood (FDA, July 2026).

Is BPC-157 orally bioavailable?

The FDA review dated 11 May 2026 and the PubMed records checked for this page on 14 October 2026 report no measurement of the oral bioavailability of BPC-157, the fraction that reaches the blood after being swallowed. The main animal pharmacokinetic study measured two routes in six animals per group, neither of them oral, and it gave the absolute bioavailability of its comparison route as about 14–19% in rats and 45–51% in dogs, values that do not describe humans or the oral route (He et al., Frontiers in Pharmacology, 2022). The FDA review dated 11 May 2026 reports no human pharmacokinetic data by the oral route, and it identified no studies establishing absolute bioavailability by an oral route in rats or dogs.

The 2008 rat fistula study, whose abstract gives no group size, measured healing outcomes rather than blood concentrations, so it does not show absorption and does not establish a human result (Klicek et al., Journal of Pharmacological Sciences, 2008).

The FDA review reports that BPC-157 resisted hydrolysis (breakdown by water) in human gastric juice in vitro, with no sample count in its summary, a test-tube result that does not establish human absorption or safety (FDA briefing document, July 2026). The FDA review's inference, not a measured result, is that peptidases in blood and tissue may explain the animal clearance measurements (FDA, July 2026).

How does the body break down and clear BPC-157?

In rats, six per group, studied with a version labelled with tritium (radioactive hydrogen), radioactivity was found in small peptide fragments and single amino acids and left through urine and bile, a radiolabel finding that does not describe humans or intact BPC-157 (He et al., Frontiers in Pharmacology, 2022). In six rats per group, the authors identified six labelled metabolites in plasma, M1 as proline and M2 to M6 as small peptide fragments, a radiolabel finding that does not measure intact BPC-157 or establish a human result (He et al., Frontiers in Pharmacology, 2022). Over 72 hours in intact rats, six per group, 15.88% of the radioactivity appeared in urine and 2.25% in faeces, a radiolabel measure that does not follow intact BPC-157 and does not describe humans (He et al., Frontiers in Pharmacology, 2022). In six rats fitted with a bile-duct cannula (a tube that collects bile), 9.08% of radioactivity appeared in bile and 17.77% in urine, a label measurement that does not follow intact BPC-157 or establish a human result (He et al., Frontiers in Pharmacology, 2022).

In six rats per time point given the labelled version, radioactivity peaked in most tissues one hour after study exposure, a radiolabel finding that does not locate intact BPC-157 or establish a human result (He et al., Frontiers in Pharmacology, 2022). In the same six rats per time point, the kidney held the most radioactivity, followed by the liver, stomach wall, spleen and thymus, and by 24 hours brain and body fat held the least, a radiolabel result that shows where the label went, not where intact BPC-157 went, and that does not describe humans (He et al., Frontiers in Pharmacology, 2022).

A peptide built to stay in the blood for days uses a different design. Retatrutide's pharmacokinetics shows what that looks like. BPC-157's published structure is a plain 15-amino-acid chain with no fatty-acid tail (FDA review, 11 May 2026).

Is research-use BPC-157 the same material the studies measured?

The studies do not establish a match. The pharmacokinetic figures on this page were measured in rats and beagle dogs, six per group, with a test substance made by the authors' own synthesis process under experimental conditions, and they do not describe humans (He et al., Frontiers in Pharmacology, 2022). Research-use reference material is a laboratory compound. The animal measurements describe what happened inside those experiments. They cannot establish the identity of other material. Research material is not a medicine, is not a substitute for one, and is not for human or animal use.

What exists for laboratory work is reference material with paperwork. The catalogue lists BPC-157 laboratory reference material with its catalogue fields, and states that Certificates of Analysis are available on request. A certificate covers the sample that was tested. The quality and verification hub explains what a certificate can and cannot show.